Market Expansion With a focus on mild-to-moderate obstructive sleep apnea and dentofacial anomalies, Vivos operates in a diagnostically underserved space where dentists and medical professionals are primary providers. Opportunities exist to expand partnerships with dental clinics, sleep clinics, and orthodontic networks to broaden adoption of The Vivos Method in new regions or countries, leveraging recent productized NAM technology.

Clinical Validation Recent press highlights robust NAM-based data and leadership in liver and intestinal toxicity models, suggesting a growing credibility halo around Vivos’ platform. Use these case studies to position the company as a trusted partner for durable clinical outcomes, potentially unlocking collaborations with mid-to-large pharma and contract research organizations seeking advanced nonanimal testing modalities.

Strategic Partnerships Notable milestones include commercial entry into China via VivoSim and milestone payments from Eli Lilly, signaling a receptiveness of large strategic investors and multinational customers. Develop outreach to large pharmaceutical, biotech, and CRO networks that value NAMkind technology for preclinical safety and translational research to diversify revenue streams.

Revenue Momentum Revenue guidance and multi-million funding activity indicate financial health and growth potential. Target cross-sell opportunities across clinics offering the Vivos Method and expand service lines around NAM-based testing platforms to capture broader demand from healthcare institutions and enterprise customers seeking AI-enabled tissue models.

Operational Footprint A mid-sized employee base signals agility with potential scalability via channel partnerships and expanded distributor networks. Focus sales efforts on dentist and medical professional training programs, while exploring regional distributors to accelerate adoption, especially in markets showing interest in noninvasive, cost-effective treatment modalities.